RCKT
Rocket Pharmaceuticals, Inc.
$3.41
-0.24 (-6.58%)
At close · Jul 16
Market Cap
$372.35M
Shares
109,193,549
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.41
Open$3.61
Day$3.41–3.63
52W$2.53–5.45
Avg vol 30d2.7M
Short int18.2M · 16.6% float · 5.0d
Short vol62%
Last earningsMay 27, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
+3%
above
RSI (14)
47
neutral
MACD trend
Negative
52-week position
30%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+22%
trailing
6-month return
−10%
trailing
YTD return
−3%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
8 of 198 funds reported for Jun 30 · net -95.4K sh shares
Insider flow
Distributing
Net -$275.0K over 90 days · 100% sells
Short interest
Falling
16.63% of float · ▼ -17.1% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
198 holders — mid 3-yr range
Squeeze score
70
high risk · 0–100
Fundamentals
EPS growth
+26%
Y/Y
Free cash flow
$-190.5M
Balance sheet
$77.6M
net cash
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−5%
Neutral
Price vs 50-day avg
+3%
Bullish
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
30%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
8 of 198 funds reported for Jun 30 · net -95.4K sh shares
Insider flow
Distributing
Net -$275.0K over 90 days · 100% sells
Short interest
Falling
16.63% of float · ▼ -17.1% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
198 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3
Now $3 · 30%
52-wk high $5
vs 200-day avg -5%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RCKT
this stock
Rocket Pharmaceuticals, Inc.
|
$372.35M | -2.8% | — | — | 16.6% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +4.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +7.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -11.9% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RCKT | -18.6% | +21.8% | -9.8% | -0.3% | -2.9% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -18.5% | +21.7% | -18.8% | -0.8% | -12.9% |